30 Jun 2025 by admin in UncategorizedComments Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
26 Jun 2025 by admin in UncategorizedComments Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
16 Jun 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
11 Jun 2025 by admin in UncategorizedComments Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
